Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,127.3
4.7 (0.15%)

 

  • STI Straits Times Index
    3,127.3
    4.7 (0.15%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,600.6
    6.0 (0.38%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,049.4
    -220.6 (-0.84%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,883.4
    3.1 (0.11%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,628.0
    9.4 (0.05%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,246.2
    -6.8 (-0.11%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,951.0
    -13.6 (-0.69%)
    Index delayed 20 minutes
  • XAO XAO
    6,593.0
    20.4 (0.31%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 642.8M
  • Value: 635.3M
  • Rise: 124
  • Fall: 153
  • Unch: 558

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
ThaiBev0.940+0.015
YZJ Shipbldg SGD0.935-0.030
SingTel3.250+0.060
Kep Infra Tr0.510-
Rex Intl0.076-0.001
Koh Eco0.053+0.002
RHT HealthTrust0.018-
Jadason^0.037+0.002
Frasers L&I Tr1.180-0.040

World Indices

World Indices
Name Last Change
Nasdaq 8,020.2 +71.7
HSI 26,055.2 -214.9
HSCEI 10,134.9 -42.4
Jakarta 6,241.1 -11.9
Nikkei 225 20,628.0 +9.4
SSE Comp 2,883.4 +3.1
Shanghai A 3,020.7 +3.3
Shanghai B 264.3 -0.5
PSE Comp 0.0
KOSPI 1,951.0 -13.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

CEL-SCI CORP CEL-SCI CORPORATION
Updated on 21 Aug 2019 (End of trading day)
Last (USD): 8.430 Change: -0.150 High: 8.610 Remarks: -
Change (%): -1.75 Low: 8.250
Open 8.440 Yesterday's Close 8.58
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 534,521 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.41015 Trailing EPS (USD) e -3.45043 NAV (USD) b 0.1228
PE a - Trailing PE f - Price / NAV b 68.6482
Dividend (USD) d - Cash In Hand (USD) g 1.0160 Issued & Paid-up Shares c 34,805,000
Dividend Yield (%) d - Price / Cash In Hand g 8.297 Treasury Shares h -
Beta - 75 Daysi -0.062 R-Squared - 75 Days(%)i 0.24 Market Cap (M) 78.702
Beta - 500 Daysi -5.572 R-Squared - 500 Days (%)i 0.13 Enterprise Value (M) 82.693
Piotroski F Score 3 Exchange Code CVM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 118.15 Free Float (%) 92.1
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 15 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CEL-SCI CORP NYSE American 78.702 - - 68.6482 -
Industry Biotechnology NYSE American 71.451 - - 2.8184 -
Local Peer 22ND CENTURY GROUP INC NYSE American 191.134 - - 3.0673 -
Local Peer PFENEX INC NYSE American 163.762 - - 3.1608 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 143.612 - - - -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 139.050 5.629 - 8.6584 -
Local Peer STANDARD DIVERSIFIED INC NYSE American 135.441 56.883 - - -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 84.688 - - 37.2929 -
Local Peer IBIO INC NYSE American 76.112 - - 11.0215 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 62.541 - - 2.0305 -
Local Peer HEMISPHERX BIOPHARMA INC NYSE American 55.993 - - 10.5126 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 54.543 - - 10.7128 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 46.309 - - - -
Local Peer INDIA GLOBALIZATION CAPITAL INC NYSE American 34.852 - - 1.0751 -
Other Local Peers ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), NANOVIRICIDES INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American)
Global Peer AMGEN INC NASDAQ 122,303.022 14.570 15.369 11.3306 2.718
Global Peer GILEAD SCIENCES INC NASDAQ 81,217.439 14.889 13.639 3.5911 3.599
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 106,623.607 39.742 39.742 14.2485 1.138
Global Peer CELGENE CORP NASDAQ 67,812.339 16.760 12.865 6.7468 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 47,911.324 22.854 21.631 9.4500 -
Global Peer BIOGEN INC NASDAQ 43,009.351 9.707 8.124 3.3204 -
Global Peer ILLUMINA INC NASDAQ 42,703.500 51.699 45.526 9.8577 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,724.340 13.387 15.815 3.3543 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,750.229 331.831 19.309 2.5336 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), GENSCRIPT BIO (HKEx), Lonza (SGX), ACADIA PHARMACEUTICALS INC (NASDAQ), 3SBIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), UNIQURE N.V. (NASDAQ), NATERA INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), REGENXBIO INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), INTREXON CORP (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), FRONTAGE (HKEx), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARVINAS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), VIVA BIOTECH (HKEx), ATARA BIOTHERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), CORTEXYME INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), PERSONALIS INC (NASDAQ), AVROBIO INC (NASDAQ), NEXTCURE INC (NASDAQ), ASCLETIS-B (HKEx), SYNTHORX INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AVITA MEDICAL LTD (ASX), AURINIA PHARMACEUTICALS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), DERMIRA INC (NASDAQ), CKLIFE SCIENCES (HKEx), SYROS PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), MERUS B V (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CHEMOCENTRYX INC (NASDAQ), IMMUNOGEN INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AGENUS INC (NASDAQ), MEDICINOVA INC (NASDAQ), ESSEX BIO-TECH (HKEx), PREVAIL THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), NEXT SCIENCE LTD (ASX), KADMON HLDGS INC (NYSE), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XBIOTECH INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), PROQR THERAPEUTICS N V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PROTAGONIST THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), GERON CORP (NASDAQ), RECRO PHARMA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), TELIX PHARMACEUTIC (ASX), EVOFEM BIOSCIENCES INC (NASDAQ), DPHARMA (Bursa), MANNKIND CORPORATION (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ARDELYX INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), CHIMERIX INC (NASDAQ), XOMA CORP (NASDAQ), ENZO BIOCHEM INC (NYSE), GLYCOMIMETICS INC (NASDAQ), IMV INC (NASDAQ), UNI-BIO GROUP (HKEx), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), BBI LIFE SCI (HKEx), MERSANA THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), TOCAGEN INC (NASDAQ), SYNLOGIC INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), ITERUM THERAPEUTICS PLC (NASDAQ), VERASTEM INC (NASDAQ), SAVARA INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), PORT (SET), CORREVIO PHARMA CORP (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VACCINEX INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), COHBAR INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), EQUILLIUM INC (NASDAQ), CURIS INC (NASDAQ), ORGENESIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ARAVIVE INC (NASDAQ), INFLARX N V (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), PHYLOGICA LIMITED (ASX), NEWLINK GENETICS CORP (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IMMUTEP LTD (ASX), VERMILLION INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), IMUGENE LIMITED (ASX), CT ENTERPRISE (HKEx), IVERIC BIO INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), REGENT PACIFIC (HKEx), BELLICUM PHARMACEUTICALS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ORTHOCELL LIMITED (ASX), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), EVOGENE LTD (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ZELDA THERAPEUTICS LTD (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), BIOCARDIA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), RHINOMED LIMITED (ASX), CONTRAFECT CORP (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIOTRON (ASX), AZURRX BIOPHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), MICROBOT MEDICAL INC (NASDAQ), BIOCEPT INC (NASDAQ), SOLIGENIX INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), MEMPHASYS LTD (ASX), HISTOGENICS CORP (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), VICAL INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PRECIPIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), TROVAGENE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), REGENEUS LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), BIONOMICS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), Suntar Eco-City^ (SGX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLMID LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENERA BIOSYSTEMS LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ATYR PHARMA INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), REXAHN PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BIOXYNE LIMITED (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), TRILLIUM THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), MGRC (Bursa), QT Vascular (SGX), ACTINOGEN MEDICAL LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), MEGASUN (Bursa), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), CCP TECHNOLOGIES LTD (ASX), OPGEN INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), MEDIBIO LIMITED (ASX), ALCHEMIA LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.040
+0.48 %
10 Days -+0.050
+0.60 %
20 Days -+1.970
+30.50 %
Medium Term Return 3 Months -+3.840
+83.66 %
6 Months -+5.590
+196.83 %
1 Year -+7.050
+510.87 %
Long Term Return 2 Years -+6.560
+350.80 %
3 Years --3.348
-28.43 %
5 Years --59.070
-87.51 %
Annualised Return Annualised --
-34.04 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1.360 - 8.990 Change From 1 Year Low +7.070 % Change From 1 Year Low (%) +519.85
Change From 1 Year High -0.560 % Change From 1 Year High (%) -6.23
2 Years Range 0.817 - 8.990 Change From 2 Years Low +7.614 % Change From 2 Years Low (%) +932.46
Change From 2 Years High -0.560 % Change From 2 Years High (%) -6.23
5 Years Range 0.817 - 27.250 Change From 5 Years Low +7.614 % Change From 5 Years Low (%) +932.46
Change From 5 Years High -18.820 % Change From 5 Years High (%) -69.06
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Aug 2019 8.440 8.610 8.250 8.430 534,521 -
20 Aug 2019 8.770 8.820 8.260 8.580 981,304 -
19 Aug 2019 8.360 8.780 8.060 8.670 754,414 -
16 Aug 2019 8.410 8.490 8.090 8.150 706,162 -
15 Aug 2019 8.210 8.840 8.110 8.390 847,044 -
14 Aug 2019 8.650 8.950 8.200 8.440 1,069,286 -
13 Aug 2019 8.080 8.790 7.970 8.750 860,469 -
12 Aug 2019 8.130 8.280 7.930 8.060 331,284 -
09 Aug 2019 8.380 8.490 7.730 8.150 609,517 -
08 Aug 2019 8.200 8.500 8.060 8.380 691,245 -
07 Aug 2019 7.710 8.317 7.310 8.150 892,220 -
06 Aug 2019 7.330 7.650 7.060 7.640 544,550 -
05 Aug 2019 7.200 7.390 6.820 7.260 460,573 -
02 Aug 2019 7.750 7.750 7.170 7.480 315,039 -
01 Aug 2019 7.170 7.720 7.170 7.570 438,144 -
31 Jul 2019 7.730 7.890 7.210 7.290 497,712 -
30 Jul 2019 7.850 7.905 7.410 7.800 451,497 -
29 Jul 2019 7.320 7.955 7.200 7.730 796,831 -
26 Jul 2019 6.450 7.220 6.261 7.100 539,648 -
25 Jul 2019 6.410 6.530 6.085 6.460 365,314 -
24 Jul 2019 6.250 6.360 6.060 6.350 255,832 -
23 Jul 2019 6.270 6.350 6.060 6.170 361,905 -
Summary
Current 2 Weeks
(08 Aug 2019 to 21 Aug 2019)		 8.200 8.950 7.730 8.430 7,385,246 -
Previous 2 Weeks
(25 Jul 2019 to 07 Aug 2019)		 6.410 8.950 6.085 8.150 5,301,528 -
4 Weeks from
(26 Jun 2019 to 24 Jul 2019)		 7.420 8.950 7.300 6.350 17,206,528 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.